• Nenhum resultado encontrado

Biological evaluation of isoniazid derivatives as an anticancer class

N/A
N/A
Protected

Academic year: 2018

Share "Biological evaluation of isoniazid derivatives as an anticancer class"

Copied!
8
0
0

Texto

Loading

Imagem

Tab. 1.    Growth Inhibition Percentage (GI %) for three Tumors Cell Lines by the MTT  Assay of compounds 1–32

Referências

Documentos relacionados

The present study describes the case of a patient with long- term psoriatic arthritis, refractory to DMARDS, who presented drug-induced hepatitis after the use of isoniazid

Disease activity level for starting biological therapy Previous use of DMARDs Choice of biological drug Switch of biological drugs Index used for assessing response to

Irrespective of the type of TNF inhibitor, patients could be divided into four categories based on drug level and the pres- ence of ADAbs: 53 (54.1%) patients had an adequate drug

The antiproliferative activity of the free Schiff bases, the copper(II) complexes and doxorubicin, the reference drug, was evaluated using seven tumor cell lines U251

Pour mener à bien notre travail de recherche, nous avons choisi de mener une enquête par voie de questionnaire, dans laquelle nous sondons des interprètes experts et

to remember that drug interactions may be beneficial or harmful, and that the quality of the drug regimen is affected by the process used to choose medica- tions based on the

The nitrated and bro- minated ellipticine derivatives prepared herein exhibit good in vitro antiplasmodial activity.. Several of the compounds studied are not toxic to human fetal

The extent of rifampicin dissolution in acidic medium in the presence of non-coated isoniazid pellets was lower than that with coated isoniazid pellets, which suggests that the